Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Frontier Medicines Corporation
National Cancer Institute (NCI)
Beijing Biotech
Continuity Biosciences, LLC
Filamon LTD
Bristol-Myers Squibb
Varian, a Siemens Healthineers Company
Minia University
National Institutes of Health Clinical Center (CC)
Allist Pharmaceuticals, Inc.
Revolution Medicines, Inc.
University of Virginia
AstraZeneca
Zhejiang University
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Verastem, Inc.
EMD Serono
Northwell Health
Medical College of Wisconsin
BicycleTx Limited
National Institutes of Health Clinical Center (CC)
Institut du Cancer de Montpellier - Val d'Aurelle
Boehringer Ingelheim
Bayer
EXACT Therapeutics AS
Akeso
Psyence Australia Pty Ltd
Akeso
Ankara Etlik City Hospital
ViroMissile, Inc.
OHSU Knight Cancer Institute
Massachusetts General Hospital
Ohio State University
Hangzhou Converd Co., Ltd.
Mayo Clinic
Dana-Farber Cancer Institute
PanTher Therapeutics
Jazz Pharmaceuticals
Sichuan Enray Pharmaceutical Sciences Company
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Amplia Therapeutics Limited